comparison of the therapeutic role of sublethal doses of selenium nanoparticles in renal inflammation and apoptosis

Cisplatin, a chemotherapy in various tumor therapies, has toxic effects on various organs, especially the kidneys. several studies have been performed to decrease its adverse effects on renal tissue using selenium (se). however, there is a limited range between selenium’s therapeutic and harmful dosages. the current work was performed to compare the therapeutic role of the sublethal doses of selenium nanoparticles (se nps) (0.5, 2, and 5 mg/kg) in cisplatin-induced renal toxicity. the experimental rats were divided into five groups. the control group (group i), group ii (cisplatin-treated group), group iii (cisplatin and 0.5 mg/kg se nps treated group), group iv (cisplatin and 2 mg/kg se nps treated group), and group v (cisplatin and 5 mg/kg se nps treated group). no statistical differences were observed in the serum urea and creatinine levels in groups i, iii, and iv.  yet, their levels were statistically elevated in group v. the renal tissue injury was improved in group iv. however, mild glomerular and tubular changes were found in group iii. in addition, renal cortical degeneration was observed in group v. these results were confirmed by the analysis of the area percent of cox2 and caspase-3 denoting that 2 mg/kg se nps represent the protective dose against acute cisplatin renal injury. the current study suggests that se nps in a dose of 2 mg/kg is beneficial in the treatment of the renal cortex against acute cisplatin injury. further research is recommended to clarify the long-term potential influences of se nps on renal toxicity.